Search

Displaying results 4391 - 4400 of 7059 in total
  1. Drug

    Buclizine

    go.drugbank.com/drugs/DB00354
    Approved

    It was manufactured by Stuart Pharms and initially approved by the FDA in 1957.

  2. Drug

    Armodafinil

    go.drugbank.com/drugs/DB06413
    ApprovedInvestigational

    (a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd.) and was approved by the U.S. Food and Drug Administration (FDA) in June 2007.

  3. Drug

    Brepocitinib

    go.drugbank.com/drugs/DB15003
    ApprovedInvestigational

    [L64097] The FDA approved brepocitinib on August 27, 2026 for the treatment of dermatomyositis in adult patients, making it the first targeted oral therapy approved for the condition.[L64115]

  4. Drug

    Avutometinib

    go.drugbank.com/drugs/DB15254
    ApprovedInvestigational

    [A273948] Avutometinib was approved by the US FDA in May 2025 in a co-package alongside [defactinib] (called Avmapki Fakzynja) for the treatment of recurrent KRAS-mutated low-grade serous ovarian cancer … Avutometinib is a small molecule kinase inhibitor targeted against RAF/MEK1, key regulators of the RAS/RAF/MEK/ERK (MAPK) pathway.

  5. Drug

    Alosetron

    go.drugbank.com/drugs/DB00969
    ApprovedWithdrawn

    In June 2002, the FDA approved a supplemental new drug application allowing the remarketing of the drug under restricted conditions of use. … Alosetron is a 5-HT3 antagonist used only for the management of severe diarrhoea-predominant irritable bowel syndrome (IBS) in women.

  6. Drug

    Sepiapterin

    go.drugbank.com/drugs/DB16326
    ApprovedInvestigational

    [L53548,L53593] Sepiapterin was granted marketing authorization by the European Commission in June 2025 and by the US FDA in July 2025 for the treatment of adults and children with phenylketonuria. … Sepiapterin is a small molecule activator of phenylalanine hydroxylase (PAH) used to reduce phenyalanine levels in patients with phenylketonuria.

  7. Drug

    Eliapixant

    go.drugbank.com/drugs/DB21465
    Investigational

    Eliapixant has a monoisotopic molecular weight of 478.13 Da. … Eliapixant is a small molecule drug. The usage of the INN stem '-pixant' in the name indicates that Eliapixant is a purinoreceptor (P2X) antagonist.

  8. Drug

    ST-36

    go.drugbank.com/drugs/DB17275
    Experimental

    ST-36 is a cell-penetrating dominant-negative form of activating transcription factor 5. In 2017, it received orphan drug designation by the FDA for the treatment of glioma.[L47341]

  9. Drug

    RR001

    go.drugbank.com/drugs/DB17369
    Investigational

    is an investigational gene therapy consisting of autologous human adipose perivascular stromal cells genetically modified to secrete soluble tumour necrosis factor-related apoptosis-inducing ligand (AD-PC

  10. Drug

    Clascoterone

    go.drugbank.com/drugs/DB12499
    ApprovedInvestigational

    [L15621] Clascoterone is also being investigated as a novel treatment for androgenetic alopecia.[A218766] … Clascoterone (cortexolone 17α-propionate, CB-03-01) is a novel antagonist of androgen receptors. It binds to androgen receptors with high affinity.